Brookline Capital Management Predicts CRBU Q1 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Brookline Capital Management issued their Q1 2025 earnings per share estimates for shares of Caribou Biosciences in a note issued to investors on Tuesday, March 11th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings of ($0.40) per share for the quarter. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.15) EPS, FY2026 earnings at ($2.24) EPS, FY2027 earnings at ($3.86) EPS and FY2028 earnings at ($1.74) EPS.

Several other research analysts have also commented on CRBU. Citigroup cut their price objective on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Friday, November 15th. Finally, Bank of America cut their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Caribou Biosciences currently has a consensus rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Trading Down 7.0 %

Shares of NASDAQ CRBU opened at $0.99 on Thursday. Caribou Biosciences has a 12 month low of $0.98 and a 12 month high of $5.94. The firm has a market capitalization of $89.24 million, a price-to-earnings ratio of -0.60 and a beta of 2.34. The business has a 50-day moving average of $1.38 and a 200-day moving average of $1.79.

Caribou Biosciences (NASDAQ:CRBU) last posted its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Institutional Trading of Caribou Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its position in Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after purchasing an additional 124,782 shares during the last quarter. Barclays PLC raised its holdings in shares of Caribou Biosciences by 122.4% during the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock valued at $255,000 after acquiring an additional 71,463 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Caribou Biosciences by 19.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock valued at $1,449,000 after acquiring an additional 118,325 shares in the last quarter. FMR LLC raised its holdings in shares of Caribou Biosciences by 7.4% during the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after acquiring an additional 109,606 shares in the last quarter. Finally, Green Alpha Advisors LLC raised its holdings in shares of Caribou Biosciences by 75.4% during the fourth quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company’s stock valued at $288,000 after acquiring an additional 77,840 shares in the last quarter. Institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.